Keywords: merck, co, suspends, enrollment, trial, lead, aurora

Merck & Co suspends enrollment in trial of lead Aurora kinase drug

Article | 26 November 2007

USA-based drug major Merck & Co has suspended enrollment in clinical trials of its lead investigational Aurora kinase inhibitor MK-0457 (VX-680), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Merck

Merck KGaA

Go to company listing